Tonix Pharmaceuticals Holding Corp. Quarterly report pursuant to Section 13 or 15(d)

STOCK BASED COMPENSATION (Tables)

6 Months Ended

Jun. 30, 2018

A summary of the stock option activity and related information for the Plans for the six months ended June 30, 2018 is as follows:

	Shares		Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term		Aggregate Intrinsic Value
Outstanding at January 1, 2018		401,724	$	39.81		8.35	$
Grants		1,004,634	$	3.79			$
Exercised		-
Forfeitures or expirations		-		-
Outstanding at June 30, 2018		1,406,358	$	14.08		9.07	$	705,284
Vested and expected to vest at June 30, 2018		1,406,358	$	14.08		9.07	$	705,284
Exercisable at June 30, 2018		323,673	$	44.43		7.34	$	47,850

The assumptions used in the valuation of stock options granted during the six months ended June 30, 2018 and 2017 were as follows:

	Six Months Ended June 30, 2018		Six Months Ended June 30, 2017
Risk-free interest rate		2.54% to 2.81%		1.77% to 2.29%
Expected term of option		4.50 to 7.00 years		5.00 to 7.91 years
Expected stock price volatility		99.65% to 102.00%		76.61% to 77.36%
Expected dividend yield		0.0%		0.0%